Retrospective Data Analysis in Crohn's Disease

NCT ID: NCT01363427

Last Updated: 2011-06-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

161 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-03-31

Study Completion Date

2010-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to identify prognostic parameters about efficacy of Mesalazine in recently diagnosed patients with Morbus Crohn by retrospective data collection.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Crohn's Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Crohn's disease

Patients with initially diagnosed Crohn's disease

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* therapeutic need according to SPC
* written informed consent
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ferring Pharmaceuticals

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ferring Pharmaceuticals

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Clinical Development Support

Role: STUDY_DIRECTOR

Ferring Pharmaceuticals

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Investigational Site, Ehrenfelsstraße 47

Berlin, , Germany

Site Status

Investigational Site, Möllendorfstraße 111

Berlin, , Germany

Site Status

Investigational Site, Graseggerstraße 105

Cologne, , Germany

Site Status

Investigational Site, Münchner Straße 64

Dachau, , Germany

Site Status

Investigational Site, Karlsbader Straße 7

Dinkelsbühl, , Germany

Site Status

Investigational Site, Heiligengrabstraße 16

Hof, , Germany

Site Status

Investigational Site, Am Tiefen Weg 2

Karlstadt am Main, , Germany

Site Status

Investigational Site, Erdbeerfeld 8

Kiel-Altenholz, , Germany

Site Status

Investigational Site, Hohenfelder Straße 20

Koblenz, , Germany

Site Status

Investigational Site, Funkenburgstraße 19

Leipzig, , Germany

Site Status

Investigational Site, Franz-Kail-Straße 2

Leverkusen, , Germany

Site Status

Investigational Site, Bahnhofplatz 2

Mainz, , Germany

Site Status

Investigational Site, Uferstraße 3

Minden, , Germany

Site Status

Investigational Site, Hammer Straße 95

Münster, , Germany

Site Status

Investigational Site, Weiltinger Str. 11

Nuremberg, , Germany

Site Status

Investigational Site, Marktplatz 23

Rottenburg, , Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

FE 999907 (Pentasa)

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.